{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T16:59:57Z","timestamp":1785517197243,"version":"3.56.0"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T00:00:00Z","timestamp":1777248000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T00:00:00Z","timestamp":1777248000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004737","name":"National Health Research Institutes","doi-asserted-by":"publisher","award":["CA-114-PP-24"],"award-info":[{"award-number":["CA-114-PP-24"]}],"id":[{"id":"10.13039\/501100004737","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastroenterol"],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The limited efficacy of immunotherapy in colorectal cancer (CRC) underscores the need to better define immunosuppressive mechanisms within the tumor microenvironment (TME). We applied single-cell RNA sequencing (scRNA-seq) to characterize stromal\u2013immune interactions shaping the CRC TME.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Paired tumor and adjacent normal mucosa samples from eight patients with CRC were analyzed by scRNA-seq. Integrated bioinformatic approaches, including trajectory inference, transcriptional regulon analysis, and cell\u2013cell communication modeling, were used to define cellular differentiation and intercellular signaling. Key findings were validated using The Cancer Genome Atlas datasets, multiplex immunofluorescence staining, and in vitro functional assays.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Trajectory analysis demonstrated a progressive increase in triggering receptor expressed on myeloid cells 1 (TREM1) expression during tumor-associated myeloid differentiation. TREM1-positive myeloid cells exhibited enriched M2-like signatures and were preferentially associated with consensus molecular subtype 4 tumors, characterized by stromal activation and poor clinical outcomes. Stromal profiling identified an \u03b1-smooth muscle actin (ACTA2)-positive population associated with CRC progression. Spatial analyses revealed close localization of TREM1-positive myeloid cells and ACTA2-positive cancer-associated fibroblasts (CAFs) in tumor tissues. Mechanistically, integrated bioinformatic analyses indicated that TREM1-positive myeloid cells engage CAFs primarily through secreted phosphoprotein 1 (SPP1) signaling, while CAFs reinforce immunosuppressive myeloid phenotypes via TGF-\u03b2-associated extracellular matrix pathways. Functional assays showed that TREM1 inhibition reduced SPP1 expression and attenuated M2 macrophage polarization.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These findings identify a bidirectional interaction between TREM1-positive myeloid cells and CAFs that contributes to a profibrotic and immunosuppressive CRC microenvironment, highlighting the TREM1\u2013SPP1 axis as a pathway of potential translational relevance.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00535-026-02430-4","type":"journal-article","created":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T17:27:26Z","timestamp":1777310846000},"page":"1104-1122","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Single-cell analysis reveals crosstalk between TREM1-positive myeloid cells and cancer-associated fibroblasts in colorectal cancer progression"],"prefix":"10.1007","volume":"61","author":[{"given":"Shang-Yin","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Po-Chuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren-Hao","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chung-Hsing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Hsuan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Jing","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing-Syuan","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Che-Hung","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsin-Yu","family":"Kuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jui-Wen","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chung-Ta","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui-Ju","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Chen","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng-Chan","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Min","family":"Yeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4086-4757","authenticated-orcid":false,"given":"Shang-Hung","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,27]]},"reference":[{"issue":"4","key":"2430_CR1","doi-asserted-by":"publisher","first-page":"495","DOI":"10.4240\/wjgs.v15.i4.495","volume":"15","author":"A Kumar","year":"2023","unstructured":"Kumar A, Gautam V, Sandhu A, et al. Current and emerging therapeutic approaches for colorectal cancer: a comprehensive review. World J Gastrointest Surg. 2023;15(4):495\u2013519.","journal-title":"World J Gastrointest Surg"},{"issue":"9","key":"2430_CR2","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.5306\/wjco.v15.i9.1136","volume":"15","author":"H Fadlallah","year":"2024","unstructured":"Fadlallah H, El Masri J, Fakhereddine H, et al. Colorectal cancer: recent advances in management and treatment. World J Clin Oncol. 2024;15(9):1136\u201356.","journal-title":"World J Clin Oncol"},{"issue":"5","key":"2430_CR3","doi-asserted-by":"publisher","first-page":"3044","DOI":"10.3390\/curroncol29050247","volume":"29","author":"Y Hiravand","year":"2022","unstructured":"Hiravand Y, Khodadadi F, Kashani SMA, et al. Immune checkpoint inhibitors in cancer therapy. Curr Oncol. 2022;29(5):3044\u201360.","journal-title":"Curr Oncol"},{"issue":"13","key":"2430_CR4","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.3748\/wjg.v30.i13.1815","volume":"30","author":"S Sharma","year":"2024","unstructured":"Sharma S, Singh N, Turk AA, et al. Molecular insights into clinical trials for immune checkpoint inhibitors in colorectal cancer: unravelling challenges and future directions. World J Gastroenterol. 2024;30(13):1815\u201335.","journal-title":"World J Gastroenterol"},{"issue":"6","key":"2430_CR5","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13061188","volume":"13","author":"IT Chyuan","year":"2021","unstructured":"Chyuan IT, Chu CL, Hsu PN. Targeting the tumor microenvironment for improving therapeutic effectiveness in cancer immunotherapy: focusing on immune checkpoint inhibitors and combination therapies. Cancers (Basel). 2021;13(6):1188.","journal-title":"Cancers (Basel)"},{"key":"2430_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.iotech.2023.100383","volume":"18","author":"M Nabhan","year":"2023","unstructured":"Nabhan M, Egan D, Kreileder M, et al. Deciphering the tumour immune microenvironment cell by cell. Immunooncol Technol. 2023;18:100383.","journal-title":"Immunooncol Technol"},{"issue":"3","key":"2430_CR7","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1016\/j.ccell.2023.02.009","volume":"41","author":"L van Vlerken-Ysla","year":"2023","unstructured":"van Vlerken-Ysla L, Tyurina YY, Kagan VE, et al. Functional states of myeloid cells in cancer. Cancer Cell. 2023;41(3):490\u2013504.","journal-title":"Cancer Cell"},{"issue":"3","key":"2430_CR8","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1007\/s13402-025-01051-y","volume":"48","author":"FS Toghraie","year":"2025","unstructured":"Toghraie FS, Bayat M, Hosseini MS, et al. Tumor-infiltrating myeloid cells; mechanisms, functional significance, and targeting in cancer therapy. Cell Oncol (Dordr). 2025;48(3):559\u201390.","journal-title":"Cell Oncol (Dordr)"},{"issue":"1","key":"2430_CR9","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s12943-025-02249-2","volume":"24","author":"SY Park","year":"2025","unstructured":"Park SY, Pylaeva E, Bhuria V, et al. Harnessing myeloid cells in cancer. Mol Cancer. 2025;24(1):69.","journal-title":"Mol Cancer"},{"issue":"5","key":"2430_CR10","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1007\/s12094-021-02734-2","volume":"24","author":"S Kamali Zonouzi","year":"2022","unstructured":"Kamali Zonouzi S, Pezeshki PS, Razi S, et al. Cancer-associated fibroblasts in colorectal cancer. Clin Transl Oncol. 2022;24(5):757\u201369.","journal-title":"Clin Transl Oncol"},{"key":"2430_CR11","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.bbrc.2023.09.065","volume":"681","author":"L Yan","year":"2023","unstructured":"Yan L, Zheng J, Wang Q, et al. Role of cancer-associated fibroblasts in colorectal cancer and their potential as therapeutic targets. Biochem Biophys Res Commun. 2023;681:127\u201335.","journal-title":"Biochem Biophys Res Commun"},{"issue":"3","key":"2430_CR12","first-page":"237","volume":"5","author":"X Wang","year":"2025","unstructured":"Wang X, Zhou Y, Wang Y, et al. Overcoming cancer treatment resistance: unraveling the role of cancer-associated fibroblasts. J Natl Cancer Cent. 2025;5(3):237\u201351.","journal-title":"J Natl Cancer Cent"},{"issue":"1","key":"2430_CR13","doi-asserted-by":"publisher","first-page":"6619","DOI":"10.1038\/s41467-022-34395-2","volume":"13","author":"H Luo","year":"2022","unstructured":"Luo H, Xia X, Huang LB, et al. Pan-cancer single-cell analysis reveals the heterogeneity and plasticity of cancer-associated fibroblasts in the tumor microenvironment. Nat Commun. 2022;13(1):6619.","journal-title":"Nat Commun"},{"issue":"1","key":"2430_CR14","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1186\/s12935-024-03518-8","volume":"24","author":"S Yu","year":"2024","unstructured":"Yu S, Wang S, Wang X, et al. The axis of tumor-associated macrophages, extracellular matrix proteins, and cancer-associated fibroblasts in oncogenesis. Cancer Cell Int. 2024;24(1):335.","journal-title":"Cancer Cell Int"},{"key":"2430_CR15","doi-asserted-by":"publisher","first-page":"1285540","DOI":"10.3389\/fimmu.2023.1285540","volume":"14","author":"S Chen","year":"2023","unstructured":"Chen S, Zhou Z, Li Y, et al. Application of single-cell sequencing to the research of tumor microenvironment. Front Immunol. 2023;14:1285540.","journal-title":"Front Immunol"},{"issue":"1","key":"2430_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.gendis.2024.101239","volume":"12","author":"W Zhang","year":"2024","unstructured":"Zhang W, Zhang X, Teng F, et al. Research progress and the prospect of using single-cell sequencing technology to explore the characteristics of the tumor microenvironment. Genes Dis. 2024;12(1):101239.","journal-title":"Genes Dis"},{"issue":"4","key":"2430_CR17","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1016\/j.ccell.2019.02.009","volume":"35","author":"L Cassetta","year":"2019","unstructured":"Cassetta L, Fragkogianni S, Sims AH, et al. Human tumor-associated macrophage and monocyte transcriptional landscapes reveal cancer-specific reprogramming, biomarkers, and therapeutic targets. Cancer Cell. 2019;35(4):588\u2013602.e10.","journal-title":"Cancer Cell"},{"key":"2430_CR18","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.canlet.2021.06.009","volume":"518","author":"Q Zhao","year":"2021","unstructured":"Zhao Q, Huang L, Qin G, et al. Cancer-associated fibroblasts induce monocytic myeloid-derived suppressor cell generation via IL-6\/exosomal miR-21-activated STAT3 signaling to promote cisplatin resistance in esophageal squamous cell carcinoma. Cancer Lett. 2021;518:35\u201348.","journal-title":"Cancer Lett"},{"issue":"11","key":"2430_CR19","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-009494","volume":"12","author":"J Kabiljo","year":"2024","unstructured":"Kabiljo J, Theophil A, Homola J, et al. Cancer-associated fibroblasts shape early myeloid cell response to chemotherapy-induced immunogenic signals in next generation tumor organoid cultures. J Immunother Cancer. 2024;12(11):e009494.","journal-title":"J Immunother Cancer"},{"key":"2430_CR20","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.907387","volume":"13","author":"S Siskind","year":"2022","unstructured":"Siskind S, Brenner M, Wang P. TREM-1 modulation strategies for sepsis. Front Immunol. 2022;13:907387.","journal-title":"Front Immunol"},{"key":"2430_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2024.107212","volume":"204","author":"C Li","year":"2024","unstructured":"Li C, Cai C, Xu D, et al. TREM1: activation, signaling, cancer and therapy. Pharmacol Res. 2024;204:107212.","journal-title":"Pharmacol Res"},{"issue":"2","key":"2430_CR22","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1111\/imm.13952","volume":"176","author":"A Palma","year":"2025","unstructured":"Palma A. The landscape of SPP1 + macrophages across tissues and diseases: a comprehensive review. Immunology. 2025;176(2):179\u201396.","journal-title":"Immunology"},{"issue":"6","key":"2430_CR23","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1038\/s41588-020-0636-z","volume":"52","author":"HO Lee","year":"2020","unstructured":"Lee HO, Hong Y, Etlioglu HE, et al. Lineage-dependent gene expression programs influence the immune landscape of colorectal cancer. Nat Genet. 2020;52(6):594\u2013603.","journal-title":"Nat Genet"},{"issue":"2","key":"2430_CR24","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1038\/s41590-018-0276-y","volume":"20","author":"D Aran","year":"2019","unstructured":"Aran D, Looney AP, Liu L, et al. Reference-based analysis of lung single-cell sequencing reveals a transitional profibrotic macrophage. Nat Immunol. 2019;20(2):163\u201372.","journal-title":"Nat Immunol"},{"issue":"7745","key":"2430_CR25","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1038\/s41586-019-0969-x","volume":"566","author":"J Cao","year":"2019","unstructured":"Cao J, Spielmann M, Qiu X, et al. The single-cell transcriptional landscape of mammalian organogenesis. Nature. 2019;566(7745):496\u2013502.","journal-title":"Nature"},{"issue":"21","key":"2430_CR26","doi-asserted-by":"publisher","DOI":"10.3390\/ijms232113277","volume":"23","author":"BS Chung","year":"2022","unstructured":"Chung BS, Liao IC, Lin PC, et al. PD-L1 expression in high-risk early-stage colorectal cancer-its clinical and biological significance in immune microenvironment. Int J Mol Sci. 2022;23(21):13277.","journal-title":"Int J Mol Sci"},{"issue":"5","key":"2430_CR27","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0268436","volume":"17","author":"MW Greene","year":"2022","unstructured":"Greene MW, Abraham PT, Kuhlers PC, et al. Consensus molecular subtype differences linking colon adenocarcinoma and obesity revealed by a cohort transcriptomic analysis. PLoS ONE. 2022;17(5):e0268436.","journal-title":"PLoS ONE"},{"key":"2430_CR28","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.3389\/fonc.2019.01512","volume":"9","author":"SD Jayasingam","year":"2020","unstructured":"Jayasingam SD, Citartan M, Thang TH, et al. Evaluating the polarization of tumor-associated macrophages into M1 and M2 phenotypes in human cancer tissue: technicalities and challenges in routine clinical practice. Front Oncol. 2020;9:1512.","journal-title":"Front Oncol"},{"issue":"1","key":"2430_CR29","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-019-0994-2","volume":"18","author":"ME Fiori","year":"2019","unstructured":"Fiori ME, Di Franco S, Villanova L, et al. Cancer-associated fibroblasts as abettors of tumor progression at the crossroads of EMT and therapy resistance. Mol Cancer. 2019;18(1):70.","journal-title":"Mol Cancer"},{"issue":"1","key":"2430_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-28480-9","volume":"13","author":"PM Szabo","year":"2023","unstructured":"Szabo PM, Vajdi A, Kumar N, et al. Cancer-associated fibroblasts are the main contributors to epithelial-to-mesenchymal signatures in the tumor microenvironment. Sci Rep. 2023;13(1):3051.","journal-title":"Sci Rep"},{"issue":"3","key":"2430_CR31","first-page":"105","volume":"3","author":"K Thanki","year":"2017","unstructured":"Thanki K, Nicholls ME, Gajjar A, et al. Consensus molecular subtypes of colorectal cancer and their clinical implications. Int Biol Biomed J. 2017;3(3):105\u201311.","journal-title":"Int Biol Biomed J"},{"key":"2430_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2023.101845","volume":"40","author":"M Sehgal","year":"2024","unstructured":"Sehgal M, Ramu S, Vaz JM, et al. Characterizing heterogeneity along EMT and metabolic axes in colorectal cancer reveals underlying consensus molecular subtype-specific trends. Transl Oncol. 2024;40:101845.","journal-title":"Transl Oncol"},{"key":"2430_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2025.102774","volume":"109","author":"W Zhu","year":"2025","unstructured":"Zhu W, Zhou Y, Wang Y, et al. TREM2 in cardiovascular diseases: mechanisms and therapeutic perspectives. Ageing Res Rev. 2025;109:102774.","journal-title":"Ageing Res Rev"},{"issue":"1","key":"2430_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-025-01152-9","volume":"9","author":"Y Huang","year":"2025","unstructured":"Huang Y, Fang W. TREM2-mediated regulation of myeloid cells in the tumor microenvironment: new insights and therapeutic prospects. NPJ Precis Oncol. 2025;9(1):359.","journal-title":"NPJ Precis Oncol"},{"issue":"21","key":"2430_CR35","doi-asserted-by":"publisher","DOI":"10.1172\/JCI167951","volume":"133","author":"A Ajith","year":"2023","unstructured":"Ajith A, Mamouni K, Horuzsko DD, et al. Targeting TREM1 augments antitumor T cell immunity by inhibiting myeloid-derived suppressor cells and restraining anti-PD-1 resistance. J Clin Invest. 2023;133(21):e167951.","journal-title":"J Clin Invest"},{"issue":"2","key":"2430_CR36","doi-asserted-by":"publisher","DOI":"10.3390\/biomimetics8020146","volume":"8","author":"K Dzobo","year":"2023","unstructured":"Dzobo K, Dandara C. The extracellular matrix: its composition, function, remodeling, and role in tumorigenesis. Biomimetics. 2023;8(2):146.","journal-title":"Biomimetics"},{"issue":"1","key":"2430_CR37","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-025-00757-3","volume":"13","author":"JJ Lee","year":"2025","unstructured":"Lee JJ, Ng KY, Bakhtiar A. Extracellular matrix: unlocking new avenues in cancer treatment. Biomark Res. 2025;13(1):78.","journal-title":"Biomark Res"},{"key":"2430_CR38","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1175343","volume":"14","author":"R Wen","year":"2023","unstructured":"Wen R, Zhou L, Peng Z, et al. Single-cell sequencing technology in colorectal cancer: a new technology to disclose the tumor heterogeneity and target precise treatment. Front Immunol. 2023;14:1175343.","journal-title":"Front Immunol"},{"issue":"1","key":"2430_CR39","doi-asserted-by":"publisher","first-page":"108","DOI":"10.3390\/jpm14010108","volume":"14","author":"L Zhao","year":"2024","unstructured":"Zhao L, Wang Q, Yang C, et al. Application of single-cell sequencing technology in research on colorectal cancer. J Pers Med. 2024;14(1):108.","journal-title":"J Pers Med"},{"key":"2430_CR40","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1217400","volume":"14","author":"Y Yuan","year":"2023","unstructured":"Yuan Y, Wu D, Li J, et al. Mechanisms of tumor-associated macrophages affecting the progression of hepatocellular carcinoma. Front Pharmacol. 2023;14:1217400.","journal-title":"Front Pharmacol"},{"key":"2430_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.216801","volume":"590","author":"M Dong","year":"2024","unstructured":"Dong M, Zhang X, Peng P, et al. Hypoxia-induced TREM1 promotes mesenchymal-like states of glioma stem cells via alternatively activating tumor-associated macrophages. Cancer Lett. 2024;590:216801.","journal-title":"Cancer Lett"},{"key":"2430_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2022.108182","volume":"238","author":"A Panagopoulos","year":"2022","unstructured":"Panagopoulos A, Samant S, Bakhos JJ, et al. Triggering receptor expressed on myeloid cells-1 (TREM-1) inhibition in atherosclerosis. Pharmacol Ther. 2022;238:108182.","journal-title":"Pharmacol Ther"},{"issue":"23","key":"2430_CR43","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.176319","volume":"9","author":"S Bale","year":"2024","unstructured":"Bale S, Verma P, Yalavarthi B, et al. Inhibiting triggering receptor expressed on myeloid cells 1 signaling to ameliorate skin fibrosis. JCI Insight. 2024;9(23):e176319.","journal-title":"JCI Insight"},{"issue":"1","key":"2430_CR44","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-020-00192-0","volume":"9","author":"H Xu","year":"2020","unstructured":"Xu H, Niu M, Yuan X, et al. CD44 as a tumor biomarker and therapeutic target. Exp Hematol Oncol. 2020;9(1):36.","journal-title":"Exp Hematol Oncol"},{"issue":"1","key":"2430_CR45","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-025-03748-4","volume":"25","author":"YJ Zhu","year":"2025","unstructured":"Zhu YJ, Li SY, Yang SS, et al. CD44 on cancer stem cell is a potential immunological and prognostic pan-cancer biomarker. Cancer Cell Int. 2025;25(1):134.","journal-title":"Cancer Cell Int"},{"issue":"1","key":"2430_CR46","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-29366-6","volume":"13","author":"J Qi","year":"2022","unstructured":"Qi J, Sun H, Zhang Y, et al. Single-cell and spatial analysis reveal interaction of FAP+ fibroblasts and SPP1+ macrophages in colorectal cancer. Nat Commun. 2022;13(1):1742.","journal-title":"Nat Commun"},{"issue":"1","key":"2430_CR47","doi-asserted-by":"publisher","first-page":"5534","DOI":"10.1038\/s41467-023-41095-y","volume":"14","author":"M Omatsu","year":"2023","unstructured":"Omatsu M, Nakanishi Y, Iwane K, et al. THBS1-producing tumor-infiltrating monocyte-like cells contribute to immunosuppression and metastasis in colorectal cancer. Nat Commun. 2023;14(1):5534.","journal-title":"Nat Commun"},{"issue":"2","key":"2430_CR48","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2024.113773","volume":"43","author":"J Giraud","year":"2024","unstructured":"Giraud J, Chalopin D, Ramel E, et al. THBS1+ myeloid cells expand in SLD hepatocellular carcinoma and contribute to immunosuppression and unfavorable prognosis through TREM1. Cell Rep. 2024;43(2):113773.","journal-title":"Cell Rep"},{"key":"2430_CR49","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2025.114906","volume":"160","author":"L Hou","year":"2025","unstructured":"Hou L, Jiang M, Li Y, et al. Targeting SPP1+ macrophages via the SPP1-CD44 axis reveals a key mechanism of immune suppression and tumor progression in ovarian cancer. Int Immunopharmacol. 2025;160:114906.","journal-title":"Int Immunopharmacol"},{"issue":"6","key":"2430_CR50","doi-asserted-by":"publisher","DOI":"10.1016\/j.mocell.2025.100215","volume":"48","author":"S Jung","year":"2025","unstructured":"Jung S, Ha J, Park JH, et al. Decoding SPP1 regulation: genetic and nongenetic insights into its role in disease progression. Mol Cells. 2025;48(6):100215.","journal-title":"Mol Cells"},{"key":"2430_CR51","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1498993","volume":"15","author":"AB Sigalov","year":"2024","unstructured":"Sigalov AB. TREM-1 and TREM-2 as therapeutic targets: clinical challenges and perspectives. Front Immunol. 2024;15:1498993.","journal-title":"Front Immunol"},{"issue":"12","key":"2430_CR52","doi-asserted-by":"publisher","first-page":"5868","DOI":"10.3390\/ijms26125868","volume":"26","author":"B Karasalih","year":"2025","unstructured":"Karasalih B, Duman H, Bechelany M, et al. Osteopontin: its properties, recent studies, and potential applications. Int J Mol Sci. 2025;26(12):5868.","journal-title":"Int J Mol Sci"},{"issue":"6","key":"2430_CR53","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24065600","volume":"24","author":"S Ben Hamouda","year":"2023","unstructured":"Ben Hamouda S, Essafi-Benkhadir K. Interplay between signaling pathways and tumor microenvironment components: a paradoxical role in colorectal cancer. Int J Mol Sci. 2023;24(6):5600.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"2430_CR54","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00384-024-04790-w","volume":"40","author":"V Kaviyarasan","year":"2024","unstructured":"Kaviyarasan V, Das A, Deka D, et al. Advancements in immunotherapy for colorectal cancer treatment: a comprehensive review of strategies, challenges, and future prospective. Int J Colorectal Dis. 2024;40(1):1.","journal-title":"Int J Colorectal Dis"},{"issue":"5","key":"2430_CR55","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e26852","volume":"10","author":"L Chen","year":"2024","unstructured":"Chen L, Huang F, Luo X, et al. TREM1 promotes cancer associated malignant phenotype through activated MAPK signaling pathway and predicts poor prognosis in gastric cancer. Heliyon. 2024;10(5):e26852.","journal-title":"Heliyon"},{"issue":"10","key":"2430_CR56","doi-asserted-by":"publisher","first-page":"2549","DOI":"10.1007\/s00262-022-03182-9","volume":"71","author":"M Thibaudin","year":"2022","unstructured":"Thibaudin M, Limagne E, Hampe L, et al. Argeting PD-L1 and TIGIT could restore intratumoral CD8 T cell function in human colorectal cancer. Cancer Immunol Immunother. 2022;71(10):2549\u201363.","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"2430_CR57","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/s00210-024-03346-7","volume":"398","author":"J Sun","year":"2025","unstructured":"Sun J, Tian Y, Yang C. Target therapy of TIGIT; a novel approach of immunotherapy for the treatment of colorectal cancer. Naunyn Schmiedebergs Arch Pharmacol. 2025;398(1):231\u201341.","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"}],"container-title":["Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-026-02430-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00535-026-02430-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-026-02430-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T16:07:45Z","timestamp":1785514065000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00535-026-02430-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,27]]},"references-count":57,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["2430"],"URL":"https:\/\/doi.org\/10.1007\/s00535-026-02430-4","relation":{},"ISSN":["0944-1174","1435-5922"],"issn-type":[{"value":"0944-1174","type":"print"},{"value":"1435-5922","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,27]]},"assertion":[{"value":"30 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no competing interests.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the ethical principles of the Declaration of Helsinki. Tissue samples were obtained from patients with colorectal cancer who underwent radical resection at National Cheng Kung University Hospital between July 2020 and December 2022. Written informed consent was obtained from all participants before surgery. The study protocol was reviewed and approved by the Institutional Review Board of National Cheng Kung University Hospital (IRB Nos. B-BR-106-068 and A-ER-114-001).","order":2,"name":"Ethics","label":"Ethical approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}}]}}